Scenic Biotech

Scenic Biotech is advancing modifier therapy, a radically new approach to treating genetic disorders. Instead of targeting the primary disease-causing mutation, modifier therapy seeks to rebalance health by acting on another function in the genome that can neutralize the disease impact, leading to a therapeutic effect. Our robust pipeline, derived from our proprietary Cell-seqTM platform, includes first-in-class small molecule programs that are either wholly owned or partnered through strategic collaborations with multinational pharmaceutical leaders. By unlocking new pathways in the genome, Scenic will develop a range of modifier therapies to help patients

Medicine,rare disease,science,technology,pharmaceuticals,biology,biotechnology,orphan disease,neurological disease,metabolic disease,drug discovery,drug development,and platform technology

Scenic biotech operates in the Biotechnology research industry.

Scenic biotech's revenue is 11m - 100m

Scenic biotech has 51 - 200 employees.